Kenneth Ssebambulidde

Kenneth Ssebambulidde

Auto-generated profile, based on publicly available information

Kenneth Ssebambulidde

Infectious Diseases Institute, Makerere University, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JJJoe Jarvis
Joe Jarvis
DLDavid S. Lawrence
David S. Lawrence
DMDavid B. Meya
David B. Meya
EKEnock Kagimu
Enock Kagimu
JKJohn Kasibante
John Kasibante
THThomas S. Harrison
Thomas S. Harrison
Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)–related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known. In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization–recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control). The primary end point was death from any cause at 10 weeks; the trial was powered to show noninferiority at a 10-percentage-point margin. A total of 844 participants underwent randomization; 814 were included in the intention-to-treat population. At 10 weeks, deaths were reported in 101 participants (24.8%; 95% confidence interval [CI], 20.7 to 29.3) in the liposomal amphotericin B group and 117 (28.7%; 95% CI, 24.4 to 33.4) in the control group (difference, −3.9 percentage points); the upper boundary of the one-sided 95% confidence interval was 1.2 percentage points (within the noninferiority margin; P<0.001 for noninferiority). Fungal clearance from cerebrospinal fluid was −0.40 log10 colony-forming units (CFU) per milliliter per day in the liposomal amphotericin B group and −0.42 log10 CFU per milliliter per day in the control group. Fewer participants had grade 3 or 4 adverse events in the liposomal amphotericin B group than in the control group (50.0% vs. 62.3%). Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment for HIV-associated cryptococcal meningitis and was associated with fewer adverse events. (Funded by the European and Developing Countries Clinical Trials Partnership and others; Ambition ISRCTN number, ISRCTN72509687.)

9 November 2023 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
LTLillian Tugume
Lillian Tugume
KSKenneth Ssebambulidde
Kenneth Ssebambulidde
JKJohn Kasibante
John Kasibante
JEJayne Ellis
Jayne Ellis
RWRachel M. Wake
Rachel M. Wake
DBDavid Boulware
David Boulware

1 August 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JRJoshua Rhein
Joshua Rhein
KHKathy Huppler Hullsiek
Kathy Huppler Hullsiek
LTLillian Tugume
Lillian Tugume
ENEdwin Nuwagira
Edwin Nuwagira
EMEdward Mpoza
Edward Mpoza
KNKirsten Nielsen
Kirsten Nielsen

30 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PRP. S. Ramachandran
P. S. Ramachandran
ARA. Ramesh
A. Ramesh
FCF. V. Cresswell
F. V. Cresswell
AWAnne Wapniarski
Anne Wapniarski
RNR. Narendra
R. Narendra
MWMichael Wilson
Michael Wilson
The epidemiology of infectious causes of meningitis in sub-Saharan Africa is not well understood, and a common cause of meningitis in this region, Mycobacterium tuberculosis (TB), is notoriously hard to diagnose. Here we show that integrating cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) with a host gene expression-based machine learning classifier (MLC) enhances diagnostic accuracy for TB meningitis (TBM) and its mimics. 368 HIV-infected Ugandan adults with subacute meningitis were prospectively enrolled. Total RNA and DNA CSF mNGS libraries were sequenced to identify meningitis pathogens. In parallel, a CSF host transcriptomic MLC to distinguish between TBM and other infections was trained and then evaluated in a blinded fashion on an independent dataset. mNGS identifies an array of infectious TBM mimics (and co-infections), including emerging, treatable, and vaccine-preventable pathogens including Wesselsbron virus, Toxoplasma gondii, Streptococcus pneumoniae , Nocardia brasiliensis , measles virus and cytomegalovirus. By leveraging the specificity of mNGS and the sensitivity of an MLC created from CSF host transcriptomes, the combined assay has high sensitivity (88.9%) and specificity (86.7%) for the detection of TBM and its many mimics. Furthermore, we achieve comparable combined assay performance at sequencing depths more amenable to performing diagnostic mNGS in low resource settings.

24 May 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JRJoshua Rhein
Joshua Rhein
KHKathy H Hullsiek
Kathy H Hullsiek
EEEmily E Evans
Emily E Evans
LTLillian Tugume
Lillian Tugume
ENEdwin Nuwagira
Edwin Nuwagira
AKAndrew Kambugu
Andrew Kambugu
Increased antiretroviral therapy (ART) availability has been associated with more patients developing cryptococcosis after ART initiation. Despite this changing epidemiology, data regarding cryptococcal meningitis in those already receiving ART are limited. We compared clinical presentations and outcomes among ART-naïve and ART-experienced Ugandans. We prospectively enrolled 605 HIV-infected persons with first-episode cryptococcal meningitis from August 2013 to May 2017 who received amphotericin-based combination therapy. We classified participants by ART status and ART duration and compared groups for 2-week survival. Overall, 46% (281/605) of participants were receiving ART at presentation. Compared with those not receiving ART, those receiving ART had higher CD4 counts (P < .001) and lower cerebrospinal fluid fungal burdens (P < .001). Of those receiving ART, 56% (156/281) initiated ART within 6 months, and 18% (51/281) initiated ART within 14 days. Two-week mortality did not differ by ART status (27% in both ART-naïve and ART-experienced%; P > .99). However, 47% (24/51) of those receiving ART for ≤14 days died within 2 weeks, compared with 19% (20/105) of those receiving ART for 15–182 days and 26% (32/125) of those receiving ART for >6 months (P < .001). Among persons receiving ART for >6 months, 87% had HIV viral loads >1000 copies/mL. Cryptococcosis after ART initiation is common in Africa. Patients initiating ART who unmask cryptococcal meningitis are at a high risk of death. Immune recovery in the setting of central nervous system infection is detrimental, and management of this population requires further study. Implementing pre-ART cryptococcal antigen screening is urgently needed to prevent cryptococcal meningitis after ART initiation.

23 February 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LTLillian Tugume
Lillian Tugume
JRJoshua Rhein
Joshua Rhein
KHKathy Huppler Hullsiek
Kathy Huppler Hullsiek
EMEdward Mpoza
Edward Mpoza
RKReuben Kiggundu
Reuben Kiggundu
DBDavid Boulware
David Boulware
Cryptococcal meningitis can occur in persons with less-apparent immunosuppression. We evaluated clinical characteristics and outcomes of persons with HIV-related Cryptococcus presenting with higher CD4 counts. We enrolled 736 participants from 2 prospective cohorts in Uganda and South Africa from November 2010 to May 2017. We compared participants with CD4 <50, 50–99, or ≥100 cells/μL by clinical characteristics, cerebrospinal fluid (CSF) parameters, and 18-week survival. Among first episode of cryptococcosis, 9% presented with CD4 ≥100 cells/μL. Participants with CD4 ≥100 cells/μL presented more often with altered mental status (52% vs 39%; P = .03) despite a 10-fold lower initial median CSF fungal burden of 7850 (interquartile range [IQR] 860–65500) versus 79000 (IQR 7400–380000) colony forming units/mL (P < .001). Participants with CD4 ≥100 cells/μL had higher median CSF levels of interferon-gamma, interleukin (IL)-6, IL-8, and IL-13, and lower monocyte chemokine, CCL2 (P < .01 for each). Death within 18 weeks occurred in 47% with CD4 <50, 35% with CD4 50–99, and 40% with CD4 ≥100 cells/μL (P = .04). HIV-infected individuals developing cryptococcal meningitis with CD4 ≥100 cells/μL presented more frequently with altered mental status despite having 10-fold lower fungal burden and with greater Th2 (IL-13) immune response. Higher CD4 count was protective despite an increased propensity for immune-mediated damage, consistent with damage-response framework. NCT01075152 and NCT01802385.